

Does Clopidogrel ^{PLAVIX} + ASA ^{ASPRIN} impact mortality?

The purpose of this Q&A is to help clarify some of the misconceptions surrounding recent publications.

BOTTOM LINE

- Compared to ASA alone, dual antiplatelet therapy (DAPT) with clopidogrel + ASA does **not** ↑ or ↓ **cardiovascular (CV) mortality**, regardless of indication.¹⁻⁷ The effect on **all-cause mortality** is less clear.
- Two meta-analyses of clopidogrel + ASA studies across **multiple indications** did not detect an ↑ risk in **all-cause mortality**.^{8,9} However, 8 meta-analyses which focused on **DAPT post drug-eluting stent** (primarily with clopidogrel + ASA) had mixed results.¹⁰⁻¹⁷
- In the largest DAPT post drug-eluting stent study to date, the potential ↑ risk of **all-cause mortality** was driven by non-CV death, specifically cancer-related death, not fatal bleeding.¹⁸
- If there is an ↑ risk in **all-cause mortality**, the absolute risk is small & it appears to only be associated in individuals with a coronary stent who are on clopidogrel + ASA longer than 1 year e.g. ≥12 vs 12 months ARI 0.4%, NNH=250.¹⁰⁻¹⁷ The benefits of clopidogrel + ASA in these individuals includes ↓ in MI NNT=71-100 & stent thrombosis NNT=143-167.¹⁰⁻¹⁷
- Until additional data is available, DAPT >1 year in patients with advanced cancer & coronary stent should be used cautiously.
- Discussion limited to clopidogrel, which has the most data. Ticagrelor & prasugrel have less safety data.

BACKGROUND

- In November 2015, the U.S. Food & Drug Administration (FDA) released a statement that long-term use of clopidogrel does not ↑ or ↓ the overall risk of death in patients with, or at risk for, heart disease based on their meta-analysis that was prompted by the **DAPT** study.^{8, 18} The meta-analysis also suggested that clopidogrel does not ↑ the risk of cancer or death from cancer.⁸

DAPT (Dual AntiPlatelet Therapy) Trial¹⁸ (see RxFiles Trial Summary)

- The **DAPT** study (drug-eluting stent [DES] analysis) compared 12 versus 30 months of DAPT post coronary stent.
- In a group of highly selected patients 56% excluded at randomization, those who were on DAPT (i.e. ASA + thienopyridine 65% clopidogrel, 35% prasugrel) for 30 months had:
 - ↓ risk of stent thrombosis (NNT=100) & ↓ risk major adverse cardiovascular & cerebrovascular event (MACCE) (NNT=63) but ↑ risk of moderate-severe bleeding (NNH=112)
- At 30 months, there was a trend of ↑ risk of **all-cause mortality** (2% vs 1.5%, p=0.05) with longer DAPT
 - this was driven by non-CV deaths (1% vs 0.5%, p=0.02)
- Between months 30 and 33, study medication was discontinued & all patients received open-label ASA. The difference in **all-cause mortality** reached a statistical significant increase (2.3% vs 1.8%, p=0.04) with a NNH=200/33 months for longer DAPT.
 - This was again driven by **non-CV deaths** (1.1% vs 0.6%, p=0.01).
 - **Non-CV death** was divided into 3 types: bleeding, trauma & cancer-related death (not mutually exclusive).
 - The ↑ risk of **non-CV death** was driven by **cancer-related deaths** (31/5020 [0.6%] vs 14/4941 [0.3%], p=0.02), not bleeding.
 - Of note, in the extended DAPT treatment arm, there was 22 more patients with a history of cancer at enrollment (488 vs 466, p=NS). Nine patients (8 vs 1) with **cancer-related deaths** had a diagnosis of cancer prior to enrollment; when these individuals were excluded from the analysis, mortality was no longer statistically significant.
- The **DAPT** investigators also conducted a separate analysis for those who received bare-metal stents (BMS), with the same trial design (i.e. 12 vs 30 months of DAPT). There was neither a ↓ in thrombosis, nor an ↑ in harm, but the study was underpowered.¹⁹
- The investigators subsequently combined their DES (85.5%) and BMS (14.5%) analyses to review the risk of mortality.²⁰
 - **All-cause mortality** was NS, but **non-CV death** was higher in the extended DAPT treatment arm (0.9% vs 0.5%, p=0.01).
 - Kaplan-Meier curves for **all-cause mortality** separated at 24 months, and continued to separate up until month 33.

Meta-Analyses

- The **DAPT** study prompted multiple meta-analyses see Table on page 2.⁸⁻¹⁷
- The FDA & **DAPT** investigators conducted MA focusing on the potential ↑ risk of mortality with clopidogrel, & included studies that spanned multiple indications.^{8,9} Both groups concluded there was no ↑ risk of **mortality** with long-term clopidogrel use.^{8,9}
- Multiple other MA were generated to compare the overall benefits & harms associated with various DAPT treatment durations.¹⁰⁻¹⁷ These 8 meta-analyses focused on the use clopidogrel + ASA post-coronary stent; all-cause mortality results were mixed.¹⁰⁻¹⁷
 - Approximately **half of the MA concluded** there was an ↑ risk of **all-cause mortality** with extended DAPT >12 months. The risk, in absolute terms, was small & varied based on the durations evaluated (absolute risk ↑ of 0.3-0.4%, NNH=250 to 334). There was no ↑ risk when abbreviated DAPT ≤6 months was compared to standard DAPT 12 months.

TABLE: COMPARISON OF THE META-ANALYSES CONDUCTED SINCE THE DAPT STUDY <small>all published in 2015</small>			
	U.S. FDA† ⁸	DAPT Investigators ⁹	Meta-Analyses on DAPT for Coronary Stents ¹⁰⁻¹⁷
Number of trials	12	14	ranged from 9 to 11
Number of patients	56,799	69,644	29,531 to 32,372
Included indications			
Atrial fibrillation: ACTIVE-A	✓	✓	-
CAD after ACS: CURE	✓	Different population, wide variance	-
CVD confirmed or high-risk: CHARISMA	✓		-
Lacunar stroke: SPS3	✓		-
PAD revascularization: CASPAR	✓		-
CAD + elective PCI: CREDO	✓	✓	-
CAD + PCI: ARTIC-Interruption	-	✓	✓
ASA-171	-	-	✓
DAPT	-	✓	✓
DES-LATE	✓	✓	Narrower population, all PCI
EXCELLENT	✓	✓	
ISAR-SAFE	-	-	✓
ITALIC	-	-	✓
OPTIMIZE	✓	✓	✓
PRODIGY	✓	✓	✓
RESET	✓	✓	✓
SECURITY	✓	✓	✓
Mortality Results			
Risk of all-cause mortality	NS	NS	<ul style="list-style-type: none"> • Study-defined longer 12, 18, 24, 30, 36 months VS shorter DAPT 3, 6, 12 months: <ul style="list-style-type: none"> - 4 MA: ↑ risk of all-cause mortality (ARI 0.3%, NNH=334)^{10,11,14,15} - 2 MA: all-cause mortality NS (1 MA p=0.05)^{12,17} • Extended DAPT >1 year vs standard DAPT 1 year: <ul style="list-style-type: none"> - 5 MA: ↑ risk of all-cause mortality (ARI 0.4%, NNH=250)^{10,11,13,14,16} - 2 MA: all-cause mortality NS (1 MA p=0.05)^{12,17} • Abbreviated ≤6 months vs standard DAPT 1 year: <ul style="list-style-type: none"> - all-cause mortality NS
Risk of cardiovascular mortality	-	NS	NS

† full meta-analysis has not been published

Clopidogrel does not decrease the risk of mortality... but this is not breaking news

- In the studies that assessed DAPT with clopidogrel, a ↓ in **mortality** was only statistically significant together with the other composite endpoint components, which was driven by the reduction in MI.¹⁻⁷ Exception: **COMMIT**, which was a study conducted in China.²¹
- **Mortality** (all-cause or cardiovascular), as a secondary endpoint was NS,¹⁻⁷ or as in the case of the **DAPT** study, potentially ↑.¹⁸

What about Ticagrelor & Prasugrel?

- In the “Additional Information” section of the FDA announcement, it is noted that prescribers should consider that prasugrel & ticagrelor have been shown to be superior to clopidogrel when used in this patient population [i.e. DAPT post PCI]. In addition, in patients with a history of MI 1 to 3 years prior to study enrollment, ticagrelor has also been shown to reduce the risk of cardiovascular death, MI, & stroke.⁸
- The above statements are based on clinical trial data, **TRITON-TIMI** (22), **PLATO** (23), **PEGASUS** (24) not the FDA meta-analysis (only included clopidogrel).
- Both Canadian & American guidelines recommend prasugrel or ticagrelor, over clopidogrel, in ACS patients with coronary stents.²⁵⁻²⁷
- **Prasugrel**: ↓ the risk of CV death as part of the composite endpoint in ACS patients undergoing PCI. Neither **all-cause mortality** nor **CV death** was statistically significant as individual secondary endpoints **TRITON-TIMI** (22)
- **Ticagrelor**:
 - In **PEGASUS**, patients who had a MI 1-3 years prior to study enrollment, both ticagrelor 60mg BID & 90mg BID ↓ **mortality** as part of the composite endpoint, compared to placebo.²⁴ However, this was primarily driven by a ↓ in MI.²⁴
 - Ticagrelor 90mg BID is the only P2Y₁₂ inhibitor that showed a ↓ in mortality – i.e. **death from vascular causes** (NNT=91/9 months) **PLATO** (23) & **death from coronary heart disease** (NNT=182/3 years), **PEGASUS** (24) but both were secondary endpoints (i.e. underpowered).
 - As of March 2016, ticagrelor has not been approved in Canada for patients with a history of MI in the previous 3 years. Ticagrelor 60mg BID is also not currently available on the Canadian market (only 90mg BID).

References available on-line www.RxFiles.ca

ACS=acute coronary syndrome ARI=absolute risk increase ASA=acetylsalicylic acid BMS=bare metal stent CAD=coronary artery disease CV=cardiovascular CVD=cardiovascular disease DAPT=dual antiplatelet therapy DES=drug-eluting stent FDA=Food & Drug Administration MA=meta-analysis/meta-analyses MI=myocardial infarction NNH=number needed to harm NNT=number needed to treat NS=non-statistically significant PAD=peripheral artery disease PCI=percutaneous coronary intervention

Acknowledgements: Contributors & Reviewers: Arden Barry, PharmD (British Columbia); Margaret Jin, PharmD (Ontario); Dr. Tom Smith-Windsor, (Saskatchewan). Prepared by: L.Kosar BSP,MSc; L. Regier BA, BSP; B. Jensen BSP, A.Crawley BSP

DISCLAIMER: The content of this newsletter represents the research, experience and opinions of the authors and not those of the Board or Administration of Saskatoon Health Region (SHR). Neither the authors nor Saskatoon Health Region nor any other party who has been involved in the preparation or publication of this work warrants or represents that the information contained herein is accurate or complete, and they are not responsible for any errors or omissions or for the result obtained from the use of such information. Any use of the newsletter will imply acknowledgment of this disclaimer and release any responsibility of SHR, its employees, servants or agents. Readers are encouraged to confirm the information contained herein with other sources. Additional information and references online at www.RxFiles.ca

Copyright 2016 – RxFiles, Saskatoon Health Region (SHR) www.RxFiles.ca

REFERENCES:

- 1) CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (**CURE**) trial programme. *Eur Heart J* 2000, 21:2033-2041.
- 2) Mehta SR, Yusuf S, Peter RJG, Bertrand ME, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the **PCI-CURE** study. *Lancet* 2001. 358:527-533.
- 3) Steinhubl SR, Berger PB, Mann JT et al; **CREDO** Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. *JAMA*. 2002 Nov 20; 288(19):2411-20.
- 4) Sabatine MS, Cannon CP, Gibson CM, et al; **CLARITY-TIMI 28** Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med*. 2005 Mar 24; 352(12):1179-89.
- 5) Sabatine MS, Cannon CP, Gibson CM, et al. Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction Treated with Fibrinolytics: The **PCI-CLARITY** Study. *JAMA*. 2005 Sept 14; 294(10): 1224-1232.
- 6) Bhatt DL, Fox KA, Hacke W, et al; **CHARISMA** Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med*. 2006 Apr 20;354(16):1706-17.
- 7) Mehta SR, Tanguay JF, Eikelboom JW, et al; **CURRENT-OASIS 7** trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (**CURRENT-OASIS 7**): a randomised factorial trial. *Lancet*. 2010 Oct 9; 376(9748):1233-43.
- 8) FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death. Available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM471586.pdf>. Accessed February 2016.
- 9) Elmariah S, Mauri L, Doros G et al Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. *Lancet*. 2015 Feb 28;385(9970):792-8.
- 10) Abo-Salem E, Alsidawi S, Jamali H, et al. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials. *Cardiovasc Ther*. 2015 Oct;33(5):253-63.
- 11) Cassese S, Byrne RA, Ndrepepa G, et al. Prolonged dual antiplatelet therapy after drug-eluting stenting: meta-analysis of randomized trials. *Clin Res Cardiol*. 2015 Oct;104(10):887-901.
- 12) Giustino G, Baber U, Sartori S, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. *J Am Coll Cardiol*. 2015 Apr 7;65(13):1298-310.
- 13) Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. *BMJ*. 2015 Apr 16;350:h1618.
- 14) Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. *Lancet*. 2015 Jun 13;385(9985):2371-82.
- 15) Spencer FA, Prasad M, Vandvik PO, et al. Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis. *Ann Intern Med*. 2015 Jul 21;163(2):118-26.
- 16) Tsoi MF, Cheung CL, Cheung TT, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials. *Sci Rep*. 2015 Aug 17;5:13204.
- 17) Verdoia M, Schaffer A, Barbieri L, et al. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials. *Angiology*. 2015 Jun 11.
- 18) Mauri L, Kereiakes DJ, Yeh RW, et al; **DAPT Study Investigators**. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. *N Engl J Med*. 2014 Dec 4; 371(23):2155-66.
- 19) Kereiakes DJ, Yeh RW, Massaro JM, et al; **DAPT Study Investigators**. Antiplatelet therapy duration following **bare metal** or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. *JAMA*. 2015 Mar 17;313(11):1113-21.
- 20) Mauri L, Elmariah S, Yeh RW et al; **DAPT Study Investigators**. Causes of late mortality with dual antiplatelet therapy after coronary stents. *Eur Heart J*. 2016 Jan 21;37(4):378-85.

- 21) Chen ZM, Jiang LX, Chen YP, et al; **COMMIT** (CLOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet*. 2005 Nov 5; 366(9497):1607-21.
- 22) Wiviott SD, Braunwald E, McCabe CH, et al; **TRITON-TIMI 38** Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2007 Nov 15; 357(20):2001-15.
- 23) Bonaca MP, Bhatt DL, Cohen M, et al; **PEGASUS-TIMI 54** Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. *N Engl J Med*. 2015 May 7;372(19):1791-800.
- 24) Wallentin L, Becker RC, Budaj A, et al; **PLATO** Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med*. 2009 Sep10;361(11):1045-57.
- 25) Tanguay JF, Bell AD, Ackman ML et al; **Canadian Cardiovascular Society**. Focused **2012** update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. *Can J Cardiol*. 2013 Nov;29(11):1334-45.
- 26) Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. **2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes**: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2014 Dec 23;64(24):e139-228.
- 27) O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions. **2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction**: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. *Catheter Cardiovasc Interv*. 2013 Jul 1;82(1):E1-27.



Drug Comparison Charts 10th Edition

**Details That
Matter**

~

**Objective &
Evidence-based
Drug Information**

www.RxFiles.ca

**Rx
FILES**

There's an APP!

Follow Us:
through email updates

OR
ON:



Geri-RxFiles 2nd Edition

